{"nctId":"NCT00446511","briefTitle":"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension","startDateStruct":{"date":"2007-06"},"conditions":["Hypertension"],"count":250,"armGroups":[{"label":"CKD patients: Valsartan+enalapril","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan","Drug: Enalapril"]},{"label":"CKD patients: Enalapril","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril","Drug: placebo matched to valsartan"]},{"label":"Non-CKD patients: Valsartan","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan","Drug: placebo matched to enalapril"]},{"label":"Non-CKD patients: Enalapril","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril","Drug: placebo matched to valsartan"]}],"interventions":[{"name":"Valsartan","otherNames":[]},{"name":"Enalapril","otherNames":[]},{"name":"placebo matched to enalapril","otherNames":[]},{"name":"placebo matched to valsartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Successful completion of 12 weeks of double-blind treatment in core protocol CVAL489K2302.\n* Patients participating in study CVAL489K2302 who may have discontinued prematurely due to uncontrolled hypertension defined as MSSBP \\> 20%, but \\< 25% above the 95th percentile for age, gender, and height after visit 5, qualifies a patient for entry into this extension study.\n\nExclusion Criteria:\n\n* Renal artery stenosis.\n* Current diagnosis of heart failure (NYHA Class II-IV).\n* Second or third degree heart block without a pacemaker.\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.\n* Clinically significant valvular heart disease.\n* Patient that demonstrates clinically significant ECG abnormalities other than those associated with left ventricular hypertrophy and AV block controlled with a pacemaker.\n* Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of immunosuppressive therapy for 3 months and deemed clinically stable by the investigator.\n* Patients who experienced any adverse events considered serious and drug related in protocol CVAL489K2302.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26","description":"After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.4","spread":"11.48"},{"groupId":"OG001","value":"-11.7","spread":"9.55"},{"groupId":"OG002","value":"-7.5","spread":"8.47"},{"groupId":"OG003","value":"-7.2","spread":"8.99"}]}]}]},{"type":"SECONDARY","title":"Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26","description":"Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \\< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"63.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20","description":"24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.3","spread":"11.60"},{"groupId":"OG001","value":"-0.3","spread":"14.42"},{"groupId":"OG002","value":"-11.5","spread":"7.81"},{"groupId":"OG003","value":"-4.1","spread":"11.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.8","spread":"3.20"},{"groupId":"OG001","value":"2.9","spread":"10.81"},{"groupId":"OG002","value":"-12.2","spread":"6.60"},{"groupId":"OG003","value":"-4.5","spread":"7.59"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26","description":"After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.6","spread":"10.79"},{"groupId":"OG001","value":"-18.2","spread":"9.51"},{"groupId":"OG002","value":"-11.6","spread":"9.74"},{"groupId":"OG003","value":"-10.2","spread":"9.70"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":21},"commonTop":["Headache","Pharyngitis","Nasopharyngitis","Pyrexia","Hyperkalaemia"]}}}